(Q33413598)

26 July 2017

Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study (English)

1 reference

multicenter clinical trial

26 July 2017

0 references

1 reference

4

Jane N Winter

1 reference

26 July 2017

Nancy L Bartlett

7

0 references

Owen A O'Connor

19

object named as

Owen A O'Connor

1 reference

26 July 2017

Michael Wang

1

1 reference

26 July 2017

Leslie L Popplewell

2

1 reference

26 July 2017

Robert H Collins

3

1 reference

26 July 2017

Andre Goy

5

1 reference

26 July 2017

Mark S Kaminski

6

1 reference

26 July 2017

Patrick B Johnston

8

1 reference

26 July 2017

John Lister

9

1 reference

26 July 2017

Suzanne R Fanning

10

1 reference

26 July 2017

Joseph M Tuscano

11

1 reference

26 July 2017

J Thaddeus Beck

12

1 reference

26 July 2017

Hakan Kaya

13

1 reference

26 July 2017

Anna Robeva

14

1 reference

26 July 2017

Jenna Fan

15

1 reference

26 July 2017

Judith Klimovsky

16

1 reference

26 July 2017

Wing Cheung

17

1 reference

26 July 2017

Azzeddine Cherfi

18

1 reference

26 July 2017

language of work or name

English

0 references

publication date

2 March 2014

1 reference

British Journal of Haematology

26 July 2017

1 reference

26 July 2017

165

1 reference

26 July 2017

4

1 reference

26 July 2017

510-518

1 reference

Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group

26 July 2017

1 reference

Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study

21 January 2018

1 reference

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

The International Harmonization Project for response criteria in lymphoma clinical trials

21 January 2018

1 reference

NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy.

21 January 2018

1 reference

Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma

21 January 2018

1 reference

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

21 January 2018

1 reference

ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma.

21 January 2018

1 reference

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma

21 January 2018

1 reference

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study

21 January 2018

1 reference

Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.

21 January 2018

1 reference

Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma

21 January 2018

1 reference

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

Genome sequencing identifies a basis for everolimus sensitivity

21 January 2018

1 reference

The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells

21 January 2018

1 reference

Is there a role for "watch and wait" in patients with mantle cell lymphoma?

21 January 2018

1 reference

PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors

21 January 2018

1 reference

Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentr

21 January 2018

1 reference

Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma

21 January 2018

1 reference

Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era

21 January 2018

1 reference

A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways.

21 January 2018

1 reference

The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma

21 January 2018

1 reference

Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma

21 January 2018

1 reference

Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma

21 January 2018

1 reference

PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs

21 January 2018

1 reference

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

21 January 2018

1 reference

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BJH.12780

1 reference

26 July 2017

1 reference